229 related articles for article (PubMed ID: 35326586)
1. Imaging of Oligometastatic Disease.
Vietti Violi N; Hajri R; Haefliger L; Nicod-Lalonde M; Villard N; Dromain C
Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326586
[TBL] [Abstract][Full Text] [Related]
2. Oligometastatic Disease (OMD): The Classification and Practical Review of Prospective Trials.
Izmailov T; Ryzhkin S; Borshchev G; Boichuk S
Cancers (Basel); 2023 Oct; 15(21):. PubMed ID: 37958408
[TBL] [Abstract][Full Text] [Related]
3. Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document.
Lievens Y; Guckenberger M; Gomez D; Hoyer M; Iyengar P; Kindts I; Méndez Romero A; Nevens D; Palma D; Park C; Ricardi U; Scorsetti M; Yu J; Woodward WA
Radiother Oncol; 2020 Jul; 148():157-166. PubMed ID: 32388150
[TBL] [Abstract][Full Text] [Related]
4. Oligo-metastatic neoPlasms from the gastro-intestinal tract: iDentIfiCaTIon of cliNical and molecular drivers: the PREDICTION study.
Ottaiano A; De Luca A; Santorsola M; Scognamiglio G; Di Mauro A; Chiodini P; Lambiase M; Sacco A; Petrillo A; Granata V; Fusco R; Mercadante E; Martucci N; De Luca G; Rocca A; Celentano E; Crispo A; Di Gennaro P; Tatangelo F; Ferrara G; Izzo F; Belli A; Patrone R; Delrio P; Rega D; De Franciscis S; Muto P; Ravo V; Di Franco R; Borzillo V; Santagata S; Rea G; Castaldo D; Pace U; De Feo G; Scala S; Nasti G; Normanno N
BMC Cancer; 2023 Oct; 23(1):1010. PubMed ID: 37858132
[TBL] [Abstract][Full Text] [Related]
5. Imaging and its Impact on Defining the Oligometastatic State.
Pirasteh A; Lovrec P; Pedrosa I
Semin Radiat Oncol; 2021 Jul; 31(3):186-199. PubMed ID: 34090645
[TBL] [Abstract][Full Text] [Related]
6. Oligometastatic colorectal cancer: prognosis, role of locoregional treatments and impact of first-line chemotherapy-a pooled analysis of TRIBE and TRIBE2 studies by Gruppo Oncologico del Nord Ovest.
Moretto R; Rossini D; Zucchelli G; Lonardi S; Bergamo F; Santini D; Cupini S; Tomasello G; Caponnetto S; Zaniboni A; Antoniotti C; Pietrantonio F; Buonadonna A; Marmorino F; Bordonaro R; Fea E; Tamburini E; Boccaccino A; Grande R; Aprile G; Falcone A; Cremolini C
Eur J Cancer; 2020 Nov; 139():81-89. PubMed ID: 32979645
[TBL] [Abstract][Full Text] [Related]
7. Strategies and technical challenges for imaging oligometastatic disease: Recommendations from the European Organisation for Research and Treatment of Cancer imaging group.
deSouza NM; Liu Y; Chiti A; Oprea-Lager D; Gebhart G; Van Beers BE; Herrmann K; Lecouvet FE
Eur J Cancer; 2018 Mar; 91():153-163. PubMed ID: 29331524
[TBL] [Abstract][Full Text] [Related]
8. Stereotactic body radiotherapy (SBRT) can delay polymetastatic conversion in patients affected by liver oligometastases.
Nicosia L; Cuccia F; Mazzola R; Figlia V; Giaj-Levra N; Ricchetti F; Rigo M; Bonù M; Corradini S; Tolia M; Alongi F
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2351-2358. PubMed ID: 32356176
[TBL] [Abstract][Full Text] [Related]
9. A risk-based approach to identifying oligometastatic disease on imaging.
deSouza NM; Tempany CM
Int J Cancer; 2019 Feb; 144(3):422-430. PubMed ID: 30098215
[TBL] [Abstract][Full Text] [Related]
10. Effects of locoregional radiotherapy in de novo metastatic nasopharyngeal carcinoma: A real-world study.
Zeng F; Lu T; Xie F; Chen L; Zhang L; Su Y; Yu Z; Xiao Y; Ao F; Li G; Chen Z; Gong X; Li J
Transl Oncol; 2021 Nov; 14(11):101187. PubMed ID: 34365221
[TBL] [Abstract][Full Text] [Related]
11. Discovery and validation of a serum microRNA signature to characterize oligo- and polymetastatic prostate cancer: not ready for prime time.
Dhondt B; De Bleser E; Claeys T; Buelens S; Lumen N; Vandesompele J; Beckers A; Fonteyne V; Van der Eecken K; De Bruycker A; Paul J; Gramme P; Ost P
World J Urol; 2019 Dec; 37(12):2557-2564. PubMed ID: 30578441
[TBL] [Abstract][Full Text] [Related]
12. Is Oligometastatic Cancer Curable? A Survey of Oncologist Perspectives, Decision Making, and Communication.
Cho HL; Balboni T; Christ SM; Turner B; Spektor A; Perni S
Adv Radiat Oncol; 2023; 8(5):101221. PubMed ID: 37124028
[TBL] [Abstract][Full Text] [Related]
13. Oligo-Metastatic Cancers: Putative Biomarkers, Emerging Challenges and New Perspectives.
Ottaiano A; Santorsola M; Circelli L; Trotta AM; Izzo F; Perri F; Cascella M; Sabbatino F; Granata V; Correra M; Tarotto L; Stilo S; Fiore F; Martucci N; Rocca A; Picone C; Muto P; Borzillo V; Belli A; Patrone R; Mercadante E; Tatangelo F; Ferrara G; Di Mauro A; Scognamiglio G; Berretta M; Capuozzo M; Lombardi A; Galon J; Gualillo O; Pace U; Delrio P; Savarese G; Scala S; Nasti G; Caraglia M
Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980713
[TBL] [Abstract][Full Text] [Related]
14. Approach to Oligometastatic Cancer in the Elderly Patient.
Winter IW; Smile TD; Videtic GMM
Curr Oncol Rep; 2021 Aug; 23(11):122. PubMed ID: 34448967
[TBL] [Abstract][Full Text] [Related]
15. A review of ongoing trials of stereotactic ablative radiotherapy for oligometastatic disease in the context of new consensus definitions.
Li GJ; Arifin AJ; Al-Shafa F; Cheung P; Rodrigues GB; Palma DA; Louie AV
Ann Palliat Med; 2021 May; 10(5):6045-6051. PubMed ID: 32787370
[TBL] [Abstract][Full Text] [Related]
16. The biology of prostate cancer metastases: does oligo differ from polymetastatic?
Sonpavde G
Curr Opin Urol; 2017 Nov; 27(6):542-546. PubMed ID: 28786848
[TBL] [Abstract][Full Text] [Related]
17. Extracranial Stereotactic Body Radiotherapy in Oligometastatic or Oligoprogressive Breast Cancer.
Weykamp F; König L; Seidensaal K; Forster T; Hoegen P; Akbaba S; Mende S; Welte SE; Deutsch TM; Schneeweiss A; Debus J; Hörner-Rieber J
Front Oncol; 2020; 10():987. PubMed ID: 32676455
[No Abstract] [Full Text] [Related]
18. Surgical management of oligometastatic disease in gastric cancer.
Jin P; Ji X; Tian Y
Clin Res Hepatol Gastroenterol; 2020 Oct; 44(5):638-645. PubMed ID: 32147440
[TBL] [Abstract][Full Text] [Related]
19. Management of Oligometastatic Disease in Esophagogastric Cancer: What Is the Evidence?
Hingorani M; Stubley H
Oncol Res Treat; 2023; 46(7-8):312-319. PubMed ID: 37331340
[TBL] [Abstract][Full Text] [Related]
20. Sec23a mediates miR-200c augmented oligometastatic to polymetastatic progression.
Sun Z; Zhou S; Tang J; Ye T; Li J; Liu D; Zhou J; Wang J; Rosie Xing H
EBioMedicine; 2018 Nov; 37():47-55. PubMed ID: 30301603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]